Hormone-refractory prostate cancer
Not recruitingStudy on the Safety and Effects of Lutetium (177Lu) Vipivotide Tetraxetan in Adults with Metastatic Castration-Resistant Prostate Cancer
Study on the Safety and Effects of Lutetium (177Lu) Vipivotide Tetraxetan in Adults with Metastatic Castration-Resistant Prostate Cancer
- Disease:Hormone-refractory prostate cancer
- Substances:GozetotideLutetium (177LU) vipivotide tetraxetan
Spain- Participants:18–64 years · 65+ years
- Substances:Gozetotide
- Sponsor:Novartis Pharma AG













